InspireMD, Inc. (NYSEAMERICAN: NSPR) Files An 8-K Other Events

InspireMD, Inc. (NYSEAMERICAN: NSPR) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On November 28, 2018, InspireMD, Inc. announced that its CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval by the Australian Therapeutic Goods Administration for commercial sale and reimbursement in Australia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description
99.1 Press release dated November 28, 2018

InspireMD, Inc. Exhibit
EX-99.1 2 ex99-1.htm     InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia   Commercial Launch to Occur Immediately   Tel Aviv,…
To view the full exhibit click here

An ad to help with our costs